JORGE E CORTES to Multicenter Studies as Topic
This is a "connection" page, showing publications JORGE E CORTES has written about Multicenter Studies as Topic.
Connection Strength
0.397
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
Score: 0.187
-
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 07 14; 13(1):92.
Score: 0.158
-
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs. 2011 Sep; 16(3):407-23.
Score: 0.021
-
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):183-9.
Score: 0.016
-
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep. 2007 May; 2(2):83-8.
Score: 0.016